Saeki Y - Search Results

1

Tissue inhibitor of metalloproteinase-3 via oncolytic herpesvirus inhibits tumor growth and vascular progenitors.

Mahller YY, Vaikunth SS, Ripberger MC, Baird WH, Saeki Y, Cancelas JA, Crombleholme TM, Cripe TP. Mahller YY, et al. Among authors: saeki y. Cancer Res. 2008 Feb 15;68(4):1170-9. doi: 10.1158/0008-5472.CAN-07-2734. Cancer Res. 2008. PMID: 18281493 Free PMC article.

2

Neuroblastoma cell lines contain pluripotent tumor initiating cells that are susceptible to a targeted oncolytic virus.

Mahller YY, Williams JP, Baird WH, Mitton B, Grossheim J, Saeki Y, Cancelas JA, Ratner N, Cripe TP. Mahller YY, et al. Among authors: saeki y. PLoS One. 2009;4(1):e4235. doi: 10.1371/journal.pone.0004235. Epub 2009 Jan 21. PLoS One. 2009. PMID: 19156211 Free PMC article.

3

Cyclophosphamide allows for in vivo dose reduction of a potent oncolytic virus.

Kambara H, Saeki Y, Chiocca EA. Kambara H, et al. Among authors: saeki y. Cancer Res. 2005 Dec 15;65(24):11255-8. doi: 10.1158/0008-5472.CAN-05-2278. Cancer Res. 2005. PMID: 16357128

4

An oncolytic HSV-1 mutant expressing ICP34.5 under control of a nestin promoter increases survival of animals even when symptomatic from a brain tumor.

Kambara H, Okano H, Chiocca EA, Saeki Y. Kambara H, et al. Among authors: saeki y. Cancer Res. 2005 Apr 1;65(7):2832-9. doi: 10.1158/0008-5472.CAN-04-3227. Cancer Res. 2005. PMID: 15805284

5

Brain tumor oncolysis with replication-conditional herpes simplex virus type 1 expressing the prodrug-activating genes, CYP2B1 and secreted human intestinal carboxylesterase, in combination with cyclophosphamide and irinotecan.

Tyminski E, Leroy S, Terada K, Finkelstein DM, Hyatt JL, Danks MK, Potter PM, Saeki Y, Chiocca EA. Tyminski E, et al. Among authors: saeki y. Cancer Res. 2005 Aug 1;65(15):6850-7. doi: 10.1158/0008-5472.CAN-05-0154. Cancer Res. 2005. PMID: 16061668

6

Triple combination of oncolytic herpes simplex virus-1 vectors armed with interleukin-12, interleukin-18, or soluble B7-1 results in enhanced antitumor efficacy.

Ino Y, Saeki Y, Fukuhara H, Todo T. Ino Y, et al. Among authors: saeki y. Clin Cancer Res. 2006 Jan 15;12(2):643-52. doi: 10.1158/1078-0432.CCR-05-1494. Clin Cancer Res. 2006. PMID: 16428511

7

Histone deacetylase inhibitors augment antitumor efficacy of herpes-based oncolytic viruses.

Otsuki A, Patel A, Kasai K, Suzuki M, Kurozumi K, Chiocca EA, Saeki Y. Otsuki A, et al. Among authors: saeki y. Mol Ther. 2008 Sep;16(9):1546-55. doi: 10.1038/mt.2008.155. Epub 2008 Jul 22. Mol Ther. 2008. PMID: 18648350 Free article.

8

Imaging immediate-early and strict-late promoter activity during oncolytic herpes simplex virus type 1 infection and replication in tumors.

Yamamoto S, Deckter LA, Kasai K, Chiocca EA, Saeki Y. Yamamoto S, et al. Among authors: saeki y. Gene Ther. 2006 Dec;13(24):1731-6. doi: 10.1038/sj.gt.3302831. Epub 2006 Jul 27. Gene Ther. 2006. PMID: 16871231

9

Development of a rapid method to generate multiple oncolytic HSV vectors and their in vivo evaluation using syngeneic mouse tumor models.

Terada K, Wakimoto H, Tyminski E, Chiocca EA, Saeki Y. Terada K, et al. Among authors: saeki y. Gene Ther. 2006 Apr;13(8):705-14. doi: 10.1038/sj.gt.3302717. Gene Ther. 2006. PMID: 16421599

10

Histone Deacetylase Inhibitors Augment Antitumor Efficacy of Herpes-based Oncolytic Viruses.

Otsuki A, Patel A, Kasai K, Suzuki M, Kurozumi K, Antonio Chiocca E, Saeki Y. Otsuki A, et al. Among authors: saeki y. Mol Ther. 2008 Sep;16(9):1546-1555. doi: 10.1038/mt.2008.155. Epub 2016 Dec 8. Mol Ther. 2008. PMID: 28189010

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

743 results

Search Page

Filters